EQL — EQL Pharma AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK670.32m
- SEK1.07bn
- SEK432.66m
Annual cashflow statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 36 | 39 | 32.6 | 67.4 | 48.7 |
| Depreciation | |||||
| Non-Cash Items | 13 | 14.2 | -5.83 | — | — |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.18 | -25.5 | -47 | -105 | -43.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 41.8 | 27.6 | -11.4 | -24.7 | 28.4 |
| Capital Expenditures | -22.1 | -20.5 | -66.3 | -246 | -67.2 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -0.001 | — | -0.001 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -22.1 | -20.5 | -66.3 | -246 | -67.2 |
| Financing Cash Flow Items | — | 0.001 | — | — | 0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5.12 | -3.88 | 53.7 | 332 | 43.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.6 | 3.23 | -24 | 61.9 | 4.36 |